Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 11:06 AM ET
Protagonist Therapeutics Inc (PTGX) P/E Ratio & Valuation History
Protagonist Therapeutics (PTGX) trades at 27.7x trailing earnings and 15.8x sales. Its P/S of 15.8x is below its 5-year median of 17.3x. Its forward P/E is 36.9x. The median P/E across 3 similar companies is 66.5x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 24.9% lower over the next year. Its free cash flow yield is 1.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 27.7x |
| Forward P/E | 36.9x |
| Price to sales | 15.8x |
| Price to book | 8.0x |
| EV/EBITDA | 25.6x |
| Price to FCF | 79.6x |
| EV/FCF | 75.1x |
| PEG | N/A |
| FCF yield | 1.3% |
Historical Medians
Against its 10-year medians, its P/B is 110.5% above 3.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 15.8x | 17.3x | N/A |
| P/B | 8.0x | 4.5x | 3.8x |
Valuation History
Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 4.7x in 2018 to 120.0x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $87.34 | N/A | 120.0x | 9.0x |
| 2024 | $38.60 | 9.2x | 5.6x | 3.8x |
| 2023 | $22.93 | N/A | 23.6x | 4.2x |
| 2022 | $10.91 | N/A | 20.0x | 2.5x |
| 2021 | $34.20 | N/A | 58.6x | 5.5x |
| 2020 | $20.16 | N/A | 24.7x | 2.9x |
| 2019 | $7.05 | N/A | N/A | 2.4x |
| 2018 | $6.73 | N/A | 4.7x | N/A |
| 2017 | $20.80 | N/A | 19.3x | N/A |
| 2016 | $21.99 | N/A | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PTGX
What is PTGX's forward P/E ratio?
Protagonist Therapeutics has a forward P/E ratio of 36.9x.
Is PTGX stock overvalued?
GNG's valuation label for PTGX is Overvalued. Its P/E of 27.7x compares with a median of 66.5x across 3 similar companies.
What is PTGX's price to sales ratio?
Protagonist Therapeutics has a price to sales ratio of 15.8x.
PTGX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors